08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Clinical Trial Management in Planegg kostenlos abonnieren.